SSI Strategy Expert Advisory Network (EAN)

About the EAN

SSI Strategy’s Expert Advisory Network connects biopharma teams with independent, conflict-checked drug development leaders – former CMOs, CEOs, and heads of development. Engagements are short and focused: scope the decision, curate the right leaders, and run a working session with clear next steps.

This curated network includes known quantities for SSI collaboration as we have worked or partnered with each member. We requested their participation as we share a similar mentality in partnership and delivery philosophy along with a proven shared track record. Collectively, we hold a passion to help our client partners achieve corporate objectives and advance therapeutic value.

Conflict-free, Independent Advisory. As external, conflict-checked advisors without sales agendas or staffing ties, we join for short, focused working sessions when a portfolio hinges on a choice, an IND needs a reset, or a story must land with investors. You get decisions, not decks—pragmatic calls from leaders who’ve done this before.

At SSI Strategy our experts stay abreast with the evolving environment and the new requirements.

John Doe

Title of Jane Doe Inc.

At SSI Strategy our experts stay abreast with the evolving environment and the new requirements.

John Doe

Title of Jane Doe Inc.

At SSI Strategy our experts stay abreast with the evolving environment and the new requirements.

John Doe

Title of Jane Doe Inc.

At SSI Strategy our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. It captures the state of the art of our industry today.

John Doe

Title of Jane Doe Inc.

At SSI Strategy our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. It captures the state of the art of our industry today.

John Doe

Title of Jane Doe Inc.

At SSI Strategy our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. It captures the state of the art of our industry today.

John Doe

Title of Jane Doe Inc.

At SSI Strategy our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. It captures the state of the art of our industry today.

John Doe

Title of Jane Doe Inc.

Who’s on the EAN

Description: Design, build, and manage high-impact board and governance structures

Approach: Provide insights on how to properly structure governance functions to set a program up for success

Usman 'Oz' Aazm

Greg Fiore

Greg Fiore

Greg Fiore

Greg Fiore

Greg Fiore

Greg Fiore

Greg Fiore

What we do together

Facilitated Workshops

Single assessment session with recommendations for next steps

Activity Examples:

  • Corporate Redesign Report
  • Board Composition Assessment
  • Investment Thesis Review & Feedback (Timeline / Milestone against Financials)
  • Operating Model Assessment
  • Portfolio Strategy Review

Executive Advisory

Ongoing strategic advisory

 

Activity Examples:

  • Board Preparations
  • Investor engagement preparation and planning
  • Change Management Strategy
  • Organizational scaling strategy
  • Senior leadership
    Onboarding strategy
  • Early-phase organizational strategy & build approach

Fixed Deliverables

Single assessment session with recommendations for next steps

Activity Examples:

  • Corporate Milestones and Program Planning
  • Organization Build Strategy and Plan
  • Portfolio Strategy Development
  • Pipeline Prioritization
  • Program Coordination and Planning
  • Development of Organizational Value Story

Compliance & Independence

EAN advisors are external, non-salaried leaders. We run pre-engagement conflict checks, pay fair-market honoraria, and never sell or recruit through advisory work. This keeps guidance independent, practical, and focused on your decisions.

From The Emerging Biotech Leader

19-06-2024

Balancing Current Needs and Long-Term Goals in Biotech : 31

In this engaging episode of the Emerging Biotech Leader podcast, Kim Kushner, Ramin Farhood, and Jackie Levine discuss the key lessons learned from the previous conversation with Dr. Dan Bloomfield, CMO at Anthos Therapeutics. The trio focuses on the ch...
19-06-2024

Redefining Roles: From Medical Practice to Biotech Ventures : 32

In this episode of the Emerging Biotech Leader podcast, hosts Kim Kushner and Ramin Farhood interview Keith Gottesdiener, President and CEO of Prime Medicine. They discuss Keith's unconventional career path, which spans roles as a physician, research sc...
19-06-2024

Oral explanation – Your product’s last stand

In this article, we provide insight into oral explanations and what you need to emphasize in a presentation in order to engage with EU regulators.

LET’S TALK

You don't have to go it alone!

Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs

This field is for validation purposes and should be left unchanged.